Maetrics, a global leader in life sciences consulting, has appointed Elizma Parry to Director of the Global Clinical Practice. A highly qualified industry professional, Elizma is a proven leader with a strong track record of clinical safety, regulatory and quality management experience. She is leading the company’s clinical practice which is dedicated to delivering effective clinical and performance evidence for international medical device and IVD regulatory compliance.
Elizma brings over 25 years of experience to the Maetrics team. Having recently been in a shared acting role as the Head of a Europe-based Notified Body before joining Maetrics, Elizma was also managing a multi-national clinical team within the Notified Body that was responsible for the clinical safety, performance and clinical benefit conformity assessments of medical device manufacturers’ clinical evidence, as well as the clinical lead for liaising with the MHRA. Elizma will provide Maetrics’ clients with expert counsel in the Clinical Practice environment.
Elizma has also worked across quality, regulatory and biotechnology environments throughout her career. She has developed and presented training courses across the UK and USA, including joint development of a bespoke Cranfield University course for Notified Body clinical assessors.
Steve Cottrell, President at Maetrics, comments: “We are thrilled that Elizma is joining the Maetrics management team. Elizma’s talent and experience combined with Maetrics’ specialist offering in international medical device and IVD regulatory compliance, means that life science companies can trust Maetrics to deliver the right clinical solutions, guidance and support to maintain their products in the European and global markets.”
Elizma adds: “I am extremely excited to start this new adventure with Maetrics. Our Clinical Practice team is here to help the Medical Device and In-vitro diagnostic industries tackle clinical requirements head on. The team and I are looking forward to supporting life science companies with a fresh and strategic perspective on clinical and performance evidence.”
